TGFB1 and neoplasm: Resveratrol has demonstrated particular promise through its multifaceted mechanisms - modulating glycolytic enzymes like PKM2 and GLUT1, suppressing TGF-β signaling, and enhancing cytotoxic T-cell responses - with preclinical studies confirming reduced tumor burden and early-phase clinical trials supporting its safety as an adjunct therapy 93.